Business Wire

c-LEcta Grows Significantly in Fiscal Year 2019, Strong Start In 2020


c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, successfully concludes 2019 and looks confidently to 2020 after a strong first quarter. The successful development of both the product business and the development partnerships resulted in a 114% increase in revenues in 2019 compared to the previous year to currently EUR 9.1 million (2018: EUR 4.2 million). Total revenues including inventory increases of finished goods and own work capitalized amounted to EUR 9.6 million (2018: EUR 4.5 million).

The company thus again grew significantly in 2019 and even exceeded its already ambitious plans. Earnings before interest, taxes, depreciation and amortization (EBITDA) also developed better than planned, slightly above break-even at EUR 0.2 million. In the previous year, the strategic realignment to concentrate on the product business had temporarily burdened EBITDA. The strong development of the product business was also the reason for the particularly good results for the full year 2019. c-LEcta had driven forward the development and distribution of its own products in particular as of recently. This strategy clearly paid off already in 2019 with product revenues growing by 181%. The existing project business in strategic partnerships also grew by 3%.

“The positive development of EBITDA in particular demonstrates the sustainability of c-LEcta’s business model. Currently, however, the strategic focus clearly remains on the further growth of the company and the investments necessary to achieve this,” said Marc Struhalla, CEO and co-founder of c-LEcta. “We are proud of last year’s revenue growth. 114% growth in one year shows us that the strategic changes of the last two years were right. This is already evident in the current year as well. We got off to a good start in 2020 thanks to the product business that has now been prioritized, and are therefore well on track for the year as a whole,” added CFO Thomas Pfaadt.

The number of employees increased further in 2019. In total, c-LEcta had 76 employees as of December 31, 2019. In the course of the year 2020, nine new employees have been hired so far. Thus c-LEcta once again proves its attractiveness as an employer and its ability to attract very good employees even in a tight job market. This will enable the company to continue to drive its current projects for development and distribution of its own products in the future.

These products are aimed at customers in both the pharmaceutical and food industries. c-LEcta is well positioned in both markets and therefore has a solid basis for further growth, especially in the current economic situation. This includes the product DENARASE, for example that is required in the production of vaccines in order to free the finished products from DNA residues from the production process. The increased demand for DENARASE in the first quarter of 2020, among other developments, has resulted in solid growth momentum in the first months of the current year.

c-LEcta again expects to expand its own product portfolio in fiscal year 2020. This includes a new enzyme product for the food sector. In the pharmaceutical sector, the introduction of an ELISA kit in the first half of 2020 will be aimed at proving the residue-free removal of DENARASE from the final product.

“Our product pipeline remains well filled. This is reflected in the product launches planned for 2020. But in the medium and long term as well, we are working on a number of promising products that each have global sales markets. In doing so, we are using our positioning with currently two primary target markets and the two segments of product business and partnerships to optimally exploit our technological platform,” commented Marc Struhalla.

Based on the good results in 2019 and the current business situation, management expects further sales growth in 2020 beyond the results that were achieved in the previous year.

About c-LEcta

c-LEcta is a world-leading biotechnology company with a focus on enzyme engineering and application in regulated markets like the food and pharma industries. The company is based in Leipzig, Germany, and has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close cooperation with industry. The company currently employs more than 80 people.

c-LEcta delivers cost-efficient and sustainable production processes which open new markets and allow for better penetration of existing markets. The company is characterized by fast and efficient development of best-in-class biotech solutions and a rapid and successful market introduction and commercialization of the resulting products. This enables c-LEcta to leverage the unique potential of its core technologies. c-LEcta has a proven track record of more than ten successfully commercialized high-value industrial biotech products.

Contact information

cometis AG
Matthias Kunz
Phone: +49 (0) 611 - 205855 – 64
Fax: +49 (0) 611 - 205855 – 66

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BCG Collaborates with Tencent Marketing Insight to Release 2020 BCG x Tencent Digital Luxury Report25.9.2020 13:21:00 EESTPress release

Since early 2020 when the COVID-19 pandemic broke out worldwide, the luxury market has been hit hard and is expected to decline 25% to 45% compared to the previous year. The Chinese luxury market, however, which has benefitted from successful domestic control of the pandemic and has taken the lead in recovery against a depressed global market environment, is forecast to grow from 20% to 30% in the whole year of 2020. Thanks to its stunning market performance, China has become the main battleground of each major luxury brand. In was in this environment that Boston Consulting Group (BCG) joined hands with Tencent Marketing Insight (TMI) to release the 2020 BCG x Tencent Digital Luxury Report, drawing on deep insights into post COVID-19 trends in the luxury market and consumers based on BCG and TMI’s quantitative consumer research and industry experience, as well as TMI’s marketing and big data capabilities. Crystal Hao, Managing Director & Partner of BCG said, “The luxury market in China

U.S. MRTP Authorization Pathway Explored in PMI’s Latest Scientific Update25.9.2020 13:15:00 EESTPress release

Philip Morris International (PMI) (NYSE: PM) has released the 11th edition of its Scientific Update, a regularly issued publication on its research efforts to develop and scientifically assess a range of smoke-free alternatives to cigarettes. The latest edition features an overview of the historic decision made by the U.S. Food and Drug Administration (FDA) to authorize the marketing of the IQOS Tobacco Heating System with reduced exposure information. The Scientific Update explains the various MRTP decisions under U.S. law; the steps, processes, and timeline PMI undertook; and the ongoing post-market surveillance and studies that will monitor the impact of the orders on consumer perceptions, behavior, and health. “The FDA undertook a scientific and regulatory evaluation of IQOS and determined that it is ‘appropriate for the promotion of public health’” said Dr. Gizelle Baker, director of Global Scientific Engagement at PMI. “In this edition of our Scientific Update, we describe how th

Palladio Completes $20 Million Series B Financing25.9.2020 13:09:00 EESTPress release

Palladio Biosciences, Inc. (Palladio), a privately-held, clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney, announced today the completion of a $20 million Series B investment. The financing was led by new investor, Samsara BioCapital, with participation from new investor, the Roche Venture Fund and existing investors, Medicxi and Osage University Partners. Proceeds from the financing will fund Palladio’s Phase 3 ALERT Study and advance operations. Srinivas Akkaraju M.D, Ph.D, Managing General Partner of Samsara BioCapital, stated, "We are very excited about our investment in Palladio to support the development of lixivaptan, a drug that has the potential to deliver a meaningful therapeutic advancement in the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The ALERT Study is an important step in assessing the safety differential of lixivaptan.” “We are very pleased that Samsara and the Roche Venture Fund recognize the opp

Ant Group Launches “Trusple,” an AntChain-Powered Global Trade and Financial Services Platform for SMEs and Financial Institutions25.9.2020 10:54:00 EESTPress release

Ant Group, a leading provider in the development of open platforms for technology-driven inclusive financial services, and the parent company of China’s largest digital payment platform Alipay, today unveiled Trusple, an international trade and financial service platform powered by AntChain, the company’s blockchain-based technology solutions. Trusple aims to make it easier and less costly for all participants – especially Small-to-Medium Enterprises (SMEs) – to sell their products and services to customers around the world. It also reduces costs for financial institutions so they can better serve SMEs in need. This press release features multimedia. View the full release here: (Photo: Business Wire) Based on the concept of “Trust Made Simple,” Trusple works by generating a smart contract once a buyer and a seller upload a trading order on the platform. As the order is executed, the smart contract is automatically updated with k

Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer25.9.2020 08:00:00 EESTPress release

Regulatory News: This press release features multimedia. View the full release here: Philippe Lopes-Fernandes, Executive Vice President, Chief Business Officer, Ipsen (Photo: Business Wire) Ipsen (Euronext: IPN; ADR: IPSEY) today announced the appointment of Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer, effective 1 October 2020. Based in Cambridge, Massachusetts, USA, he will be responsible for business development and alliance management, reporting directly to David Loew, CEO, Ipsen. Philippe will serve on the Executive Leadership Team. “As Chief Business Officer, Philippe will play a crucial role in our external innovation strategy. The ELT and I are delighted to welcome Philippe to Ipsen and look forward to working closely with him. His extensive and impressive track record in international business development, his outstanding reputation and his ability to work closely with the scientific comm

Deloitte Launches < "The Next Wave" Emerging Digital Life in South and Southeast Asia > Report At Ant Group’s INCLUSION Fintech Conference25.9.2020 06:45:00 EESTPress release

Deloitte launched <"The Next Wave" Emerging Digital Life in South and Southeast Asia > Report today at the INCLUSION Fintech Conference, organized by Ant Group and Alipay to foster a global dialogue on building a more inclusive, green, and sustainable world through digital technology. This press release features multimedia. View the full release here: (Graphic: Business Wire) Through an extensive survey conducted across age groups in eight countries in South and Southeast Asia, specifically Singapore, Malaysia, Thailand, Indonesia, the Philippines, India, Bangladesh and Pakistan, the report showed that consumers aged between 21 and 40 years old are the leading force enabling the rapid adoption of a digital life in the region in the post Covid-19 world. Speaking at one of the media forums on Day 2 of INCLUSION, Taylor Lam, Technology, Media & Telecommunications Industry Leader at Deloitte China, said: “Young and vibrant economies

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom